Actions
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
3
Neutral
6
Bullish
5
Bearish
19
Neutral
6
Bullish
21
Bearish
16
Neutral
0
Bullish
16
Bearish
16
Neutral
0
Bullish
16
Bearish
16
Neutral
0
Bullish
16
Bearish
16
Neutral
0
Bullish
16
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone

Krsnaa Diagnostics Ltd (KRSNAA) is currently trading at 516.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Krsnaa Diagnostics Limited provides integrated pathology, radiology, teleradiology and related diagnostic services across India, primarily through public-private partnership, institutional and retail channels. Its offering includes CT, MRI, X-ray, PET/CT, laboratory testing and specialized preventive-health diagnostics, with a strong presence in rural and underserved locations. Krsnaa Diagnostics crossed INR500 crore of consolidated revenue in the first half of FY27, reaching INR507 crore and growing 27% year-on-year despite contract completions. Management said growth could have approached 37% if certain contracts had continued, highlighting the company’s ability to replace maturing projects with new opportunities. The company operates a large PPP-led network across 19 states and union territories, including 259 pathology laboratories, 196 CT and MRI centers and more than 8,400 patient touch points. Approximately 75% of centers cover rural India, making geographic reach and public-health access central to Krsnaa Diagnostics’ operating model. Growth is currently accompanied by working-capital pressure: receivables reached approximately INR470 crore, although management expects around INR200 crore of collections during Q3 FY27. The company is deliberately increasing cash-based revenue, targeting 40%–45% of FY27 revenue, or approximately INR400 crore, to improve liquidity and reduce financing dependence. Retail is emerging as a meaningful growth engine, with Q2 FY27 revenue of approximately INR23.5 crore, 35% year-on-year revenue growth, 45% patient-volume growth and 48% test-volume growth. Retail represented around 9% of group revenue, was operationally near breakeven in September, and management expects positive EBITDA contribution while scaling toward higher-teens or 20%-plus share over time.
Over the past 52 weeks, Krsnaa Diagnostics Ltd has traded between a low of ₹462.10 and a high of ₹834.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Krsnaa Diagnostics Ltd has a market capitalization of approximately 1,655.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Krsnaa Diagnostics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 16.88 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,655.83 Cr, Krsnaa Diagnostics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Krsnaa Diagnostics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Krsnaa Diagnostics Ltd is 16.88. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Management said Rajasthan has the potential to generate about Rs 250 crore on an annualised basis. It said the majority of that annualised contribution is expected in the next financial year because implementation and revenue generation began during the current year.
Krsnaa said cash-based PPP projects currently account for around 35%-38% of overall revenue. Management is targeting a 40%-45% contribution in FY27 through selective project additions and tender participation.
Krsnaa said its retail diagnostics business was operationally break-even in September, the final month of Q2 FY27. Management distinguished this from absolute break-even because brand and marketing spending is still required. It expects absolute break-even by Q3 FY27 or early Q4 FY27.
Krsnaa reported receivables of approximately Rs 470 crore at September 30, 2026. Management attributed the balance to business expansion, the early billing cycle of Rajasthan and payment delays from certain government authorities.

Healthcare Services
Healthcare Service Provider
1,675 Cr
Low Risk
17.08
60.90
1.37
1.59
834.90
462.10
Sales CAGR
Profit CAGR
ROE
ROCE